China’s Tasly to list biotech arm in $1 billion Hong Kong IPO: sources

HONG KONG (Reuters) – China’s Tasly Pharmaceutical Group is planning to list its biopharma unit in Hong Kong to raise about $1 billion, in what is likely to be the largest biotech float in the city this year, people with knowledge of the matter said.
( read original story …)


Related Post

How to Open a Bank Account in Hong Kong
views 6
Hong Kong – an international business hub and gate...
Opening a Bank Account in Hong Kong: Challenges an...
views 15
Hong Kong – an international business hub and gate...
Hong Kong University Receives $20 Mln Research Gra...
views 14
The Hong Kong University of Science and Technology...
Digital payment fight brewing in Hong Kong
views 16
HONG KONG: Hong Kong's shopping districts are well...
Hong Kong: HANG SENG INDEX (.HSI) ended 0.8 percen...
views 18
The Shanghai Composite Index .SSEC closed down 0.6...
Hong Kong Dollar Funding Costs Surge After HKMA De...
views 17
Hong Kong’s interbank borrowing costs climbed acro...
Hong Kong Spends $2.1 Billion This Week to Defend ...
views 16
(Bloomberg) -- Hong Kong’s currency interventions ...
Industrial Bank Co., Ltd creates Hong Kong private...
views 17
Fuzhou-headquartered Industrial Bank Co., Ltd, one...
Industrial Bank Co., Ltd creates new Hong Kong Pri...
views 17
Fuzhou-headquartered Industrial Bank Co., Ltd, one...
Digital payment firms fight for Hong Kong market
views 18
HONG KONG (Reuters) - Hong Kong’s shopping distric...